Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05992935 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
A Phase 1 study of Norovirus Acute Gastroenteritis, sponsored by ModernaTX.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 1,405
- Enrollment target
- 16
- Study locations
NCT05992935: Recruiting Phase 1 study of Norovirus Acute Gastroenteritis, sponsored by ModernaTX.
NCT05992935 is a Phase 1 study of Norovirus Acute Gastroenteritis that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 1,405 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (2242% higher). The trial reports 16 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05992935, a Phase 1 study of Norovirus Acute Gastroenteritis, is actively recruiting participants, sponsored by ModernaTX.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 1,405 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of the Part A Phase 1 of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 to 49 years of age and 60 to 80 years of age. The purpose of Part B Phase 2 and Part C Phase 2 is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 in healthy adult participants (18 to 80 years of age).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1403
- BIOLOGICAL mRNA-1405
Study Locations (16)
Nebraska
- Velocity Clinical Research - Norfolk
- Velocity Clinical Research - Omaha
Other
- Emeritus Research Camberwell - Camberwell
- Nucleus Network - Melbourne
California
- ARK Clinical Research, LLC - Long Beach
Colorado
- Tekton Research, Inc - Longmont Center - Longmont
Florida
- Research Centers of America - Hollywood
Georgia
- Accel Research Sites Network - Decatur
Idaho
- Velocity Clinical Research - Boise - Meridian
Illinois
- Optimal Research - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,405 participants |
| Start Date | 2023-08-25 |
| Est. Completion | 2026-09-22 |
| Phase | Phase 1 |
What NCT05992935 shows while recruiting
NCT05992935 is an interventional study that assigns participants to a tested intervention. Its 1,405 participants enrollment target places it among the larger protocols in the corpus, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (2242% higher).
The record links to 1 condition, with Norovirus Acute Gastroenteritis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05992935 lists 16 locations in 14 states (Nebraska, Other, California).
Frequently Asked Questions
What is clinical trial NCT05992935 about?
NCT05992935 is a clinical study titled "Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age". The purpose of the Part A Phase 1 of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 to 49 years of age and 60 to 80 years of age. The purpose of Part B Phase 2 and Part C Phase 2 is to evaluate the safety, reactoge...
What is the current status of trial NCT05992935?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 1,405 participants. The study started on 2023-08-25. Estimated completion is 2026-09-22.
What conditions does trial NCT05992935 study?
This clinical trial studies the following conditions: Norovirus Acute Gastroenteritis.
What interventions are being tested in trial NCT05992935?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1403 (BIOLOGICAL), mRNA-1405 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05992935?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05992935 being conducted?
This trial has 16 study locations across California, Colorado, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Norovirus Acute Gastroenteritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05992935's enrollment target sits among peer trials
1,405 3rd of 2000 higher than 1,998 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05444582 · 1,404 participants · Phase 4
Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start
- NCT05890404 · 1,410 participants · NA
SGM Evidenced-Based Mental Healthcare Implementation
- NCT07042451 · 1,410 participants · NA
An Evaluation of the Pink Cloud Application in Post- Treatment Substance Use Disorder Support
- NCT07222566 · 1,410 participants · Phase 3
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI